| 肿瘤免疫治疗的进展——靶向阻断负性免疫调节分子 |
| |
| 引用本文： | 郑芳,李慧玉.肿瘤免疫治疗的进展——靶向阻断负性免疫调节分子[J].国际免疫学杂志,2014,37(4):276-279. |
| |
| 作者姓名： | 郑芳 李慧玉 |
| |
| 作者单位： | 郑芳 (华中科技大学同济医学院附属协和医院儿科,武汉,430022)； 李慧玉 (华中科技大学同济医学院附属协和医院干细胞研究与应用中心,武汉,430022)； |
| |
| 基金项目： | 国家自然科学基金(项目编号：81301954) |
| |
| 摘 要： | 肿瘤免疫治疗具有靶向抗肿瘤作用而成为人们研究的热点.然而,肿瘤细胞通过多种途径诱导“免疫豁免”效应,削弱免疫治疗的疗效.大量研究表明,在T细胞活化中,一些关键性负性免疫调节分子是肿瘤诱导免疫耐受的重要机制.因此,靶向阻断这些负性免疫调节分子在增强抗肿瘤免疫应答中具有重要意义.
|
| 关 键 词： | 肿瘤 免疫治疗 分子靶向治疗 细胞毒性T淋巴细胞相关抗原4 程序性死亡因子1 |
Research progress about targeting immune checkpoints in cancer immunotherapy |
| |
| Institution: | ZHENG Fang,LI Huiyu( Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China) |
| |
| Abstract: | Cancer immunotherapy is an important focus of research because of its potential for inducing tumour-specific immune responses.However,this antitumor effect is failed to lead to the tumor regression that may be due to immunoevasive of tumors.It is now clear that many immune checkpoints play an important role in T cell-activation,and tumour-specific immune-checkpoint pathways may represent a major mechanism of immune resistance.Thus,we suggest that the promising approach for enhancing therapeutic antitumor immunity is the blockade of these immune checkpoints. |
| |
| Keywords: | Neoplasms Immunotherapy Molecular Targeted therapy Cytotoxic T lymphocyte-associated antigen-4 Programmed death-1 |
| 本文献已被 维普 等数据库收录！ |
|
